On November 4, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that IMM27M, the newly developed ADCC-enhanced CTLA-4 antibody was approved by NMPA for clinical trial research. This is another major milestone for ImmueOnco.

CTLA-4 is the first clinically proven check point for immunotherapy, as the first antibody approved in 2011, Ipilimumab is still the only approved drug in the global market. Three weeks ago, the first prescription came out priced at￥28,000 per dose in China.

The IMM27M is an IgG1 antibody targeting CTLA-4. It has been genetically modified to enhance ADCC activity. In the preclinical research, IMM27M appeared to be more efficacious than that of Ipilimumab since it completely removes tumors at a lower dose (0.3 mg/kg) in animal models.

Dr. Tian, Wenzhi, the founder and chairman of ImmueOnco said,

"We are pleased that our next-generation CTLA-4 antibody program has been approved by NMPA for clinical trial research. Repeatable in vivo studies have demonstrated that IMM27M has robust anti-tumor activity and also, can be used in combination with a variety of drugs in the company's pipeline for clinical research. We believe that the IMM27M has great value for clinical development. ”

"We will make our best to develop IMM27M to benefit more patients."